The future is rich with potential for medical technology — and a better, connected patient experience is at the center of it. Improving lives by bringing more advanced care closer to home is not only possible but emerging rapidly.
For decades, Phillips-Medisize, a Molex company, has been laser focused on contract design and manufacturing of products in highly regulated industries such as MedTech, where precision, reliability and quality are critical.
Game-changing product, transparent teamwork and world-class manufacturing have amplified patient screenings for early cancer detection. Thanks to a powerful collaboration between Phillips-Medisize and Exact Sciences.
When developing next-gen medical solutions that perform with optimal precision, exhaustive design research is critical including first-hand observations. Interpreting clinical requirements and discovering what’s intuitive to practitioners while administering patient care is table stakes for successful design and development.
The upsurge in connected heath has resulted in healthcare companies needing to shift from producing purely mechanical medical devices to connected devices that now require embedded electronics and software, which complicates the design in terms of functionality, size, form factor and manufacturability.
Drug delivery requirements are becoming more challenging, placing increased pressure on building time-to-market designs that are not only easy to use but also support faster time-to-market delivery and a strong focus on sustainability. As a result, the pharmaceutical industry is experiencing an emerging reliance on companies that can support integrated, end-to-end device development and drug and reagent handling – all under one roof.
Exact Sciences, a leader in cancer testing, developed a game-changing at-home colorectal cancer kit, but needed support to build the highest quality product. With decades of manufacturing innovation for healthcare and life sciences companies, Exact Sciences found a quality-first collaborator in Phillips-Medisize.
Is digital drug delivery going mainstream? In a new Molex and Phillips-Medisize survey of 215 pharma executives, nearly 90% said it’s “extremely or very important.” The survey also reveals current adoption and the perceived benefits and barriers of digital drug delivery. Use these critical insights to inform planning and decision making — and to stay ahead of this rapidly evolving, growing market.
Product realization is an inherently unpredictable journey through new unknowns. The challenges of bringing next-generation products to market are magnified in highly regulated industries where even the tiniest inconsistency can impact efficacy and outcomes — which affects your brand and diminishes profit. Industry-leading innovation needs industry-leading expertise and laser focus on minimizing risk. Achieve fast, high-quality healthcare product realization with Phillips-Medisize, a Molex company.
Bringing Possibilities to Life
Tap into the competitive value of our expertise, drawn from decades of working with top healthcare OEMs.
